Skip to main content
SpringerLink
Log in

Zielgerichtete Therapien bei hämatologischen Erkrankungen

Standards und Perspektiven

Targeted therapy of hematological diseases

Standards and perspectives

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Hintergrund

Das Verständnis der Biologie hämatologischer Erkrankungen und die detaillierte Kenntnis der Signaltransduktion in normalen und malignen Zellen sowie die Zahl der bekannten zytogenetischen und molekularen Veränderungen nehmen rasant zu. Die Anwendung neuer zielgerichteter Therapieoptionen ist an eine komplexe morphologische, immunologische und genetische Diagnostik gebunden. Die klassischen Krankheitsentitäten werden diversifiziert. Neue Klassifikations- und Scoringsysteme bieten Grundlagen für risikoadaptierte und subgruppenspezifische Therapiestrategien.

Ziel

Der Beitrag stellt die aktuellen Möglichkeiten der Anwendung zielgerichteter Therapien bei malignen hämatologischen Erkrankungen mit zugelassenen Medikamenten und in klinischen Studien dar und zeigt Entwicklungslinien auf.

Material und Methode

Recherche und Auswertung von Literatur.

Schlussfolgerungen

Nach Einführung des CD20-Antikörpers Rituximab in die Therapie maligner B-Zell-Lymphome und von Imatinib in die Therapie der chronischen myeloischen Leukämie (CML) hat sich die Anwendung zielgerichteter Therapien in der Hämatologie rasant entwickelt. Die Kenntnis der krankheitsspezifischen Signaltransduktionswege ist von enormer Bedeutung für die Entwicklung geeigneter Therapien.

Abstract

Context

Knowledge of the biology of hematological diseases and signal transduction in normal and malignant cells as well as the number of known cytogenetic and molecular changes are rapidly increasing. The application of targeted therapy options is linked to complex morphological, immunological and genetic diagnostics. The classical disease entities have been diversified. New classification and scoring systems provide the basis for risk-adapted and subgroup-specific treatment strategies.

Objective

This review summarizes the current options of the application of targeted therapy of hematological malignancies with approved drugs and in clinical trials and presents some developmental perspectives.

Material and method

Research and analysis of the literature.

Conclusions

After introduction of the CD20 antibody rituximab in the therapy of malignant B-cell lymphoma and imatinib in the therapy of chronic myeloid leukemia (CML) the use of targeted therapies in hematology has rapidly developed. Knowledge of disease-specific signal transduction pathways is of enormous importance for the development of suitable therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Byrd JC, Furman RR, Coutre SE, et al. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32–42

    Article  PubMed  CAS  Google Scholar 

  2. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

    Article  PubMed  CAS  Google Scholar 

  3. Attal M, Lauwers-Cances V, Marit G et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782–1791

    Article  PubMed  CAS  Google Scholar 

  4. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. doi:10.1182/blood-2013-05-501569 (blood-2013-05-501569; published ahead of print)

  5. Barrans SL, Crouch S, Care MA et al (2012) Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol 159:441–453

    Article  PubMed  CAS  Google Scholar 

  6. Brunet S, Labopin M, Esteve J et al (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 30:735–741

    Article  PubMed  Google Scholar 

  7. Burnett AK, Hills RK, Hunter AE et al (2013) The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 27:75–81

    Article  PubMed  CAS  Google Scholar 

  8. Burnett AK, Russell NH, Hills RK et al (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924–3931

    Article  PubMed  CAS  Google Scholar 

  9. Castaigne S, Pautas C, Terre C et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379(9825):1508–1516

    Article  PubMed  CAS  Google Scholar 

  10. Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359:613–626

    Article  PubMed  CAS  Google Scholar 

  11. Cheson BD (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28:3525–3530

    Article  PubMed  CAS  Google Scholar 

  12. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  PubMed  CAS  Google Scholar 

  13. Cortes JE, Kantarjian H, Shah NP et al (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075–2088

    Article  PubMed  CAS  Google Scholar 

  14. Cortes JE, Kim DW, Kantarjian HM et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30:3486–3492

    Article  PubMed  CAS  Google Scholar 

  15. Czuczman MS, Weaver R, Alkuzweny B et al (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711–4716

    Article  PubMed  CAS  Google Scholar 

  16. Deng C, Pan B, O’Connor OA (2013) Brentuximab vedotin. Clin Cancer Res 19:22–27

    Article  PubMed  CAS  Google Scholar 

  17. Dunleavy K, Pittaluga S, Czuczman MS et al (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069–6076

    Article  PubMed  CAS  Google Scholar 

  18. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    Article  PubMed  CAS  Google Scholar 

  19. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562–569

    Article  PubMed  CAS  Google Scholar 

  20. Frankel SR, Baeuerle PA (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 17:385–392

    Article  PubMed  CAS  Google Scholar 

  21. Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518

    Article  PubMed  CAS  Google Scholar 

  22. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174

    Article  PubMed  CAS  Google Scholar 

  23. Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798

    Article  PubMed  CAS  Google Scholar 

  24. Hochhaus A, Ernst T, Ziermann J et al (2012) Chronische myeloische Leukämie. Onkologe 18:1105–1114

    Article  Google Scholar 

  25. Hochhaus A, Kreil S, Corbin AS et al (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196

    Article  PubMed  CAS  Google Scholar 

  26. Hochhaus A, Lüftner D, Mackensen A (2013) Gezielte Therapie: alte und neue Hoffnungsträger. Onkologie 36(Suppl 5):2–11

    Article  PubMed  Google Scholar 

  27. Ito T, Ando H, Suzuki T, Ogura T et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345–1350

    Article  PubMed  CAS  Google Scholar 

  28. Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270

    Article  PubMed  CAS  Google Scholar 

  29. Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677

    Article  PubMed  CAS  Google Scholar 

  30. Kluin-Nelemans HC, Hoster E, Hermine O et al (2012) Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520–531

    Article  PubMed  CAS  Google Scholar 

  31. Koreth J, Schlenk R, Kopecky KJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349–2361

    Article  PubMed  CAS  Google Scholar 

  32. Leleu X, Attal M, Arnulf B et al (2013) Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 121:1968–1975

    Article  PubMed  CAS  Google Scholar 

  33. Lo Coco F, Avvisati G, Orlando SM et al (2012) ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for newly diagnosed, non high-risk Acute Promyelocytic Leukemia (APL): results of the phase III, prospective, randomized, intergroup APL0406 study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. N Engl J Med 369:111–121

    Google Scholar 

  34. Lokhorst H, Einsele H, Vesole D et al (2010) International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 28:4521–4530

    Article  PubMed  Google Scholar 

  35. McCarthy PL, Owzar K, Hofmeister CC et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770–1781

    Article  PubMed  CAS  Google Scholar 

  36. Metzgeroth G, Lengfelder E, Griesshammer M, Reiter A (2012) BCR-ABL-negative myeloproliferative Neoplasien. Onkologe 18:1130–1138

    Article  Google Scholar 

  37. Morschhauser F, Radford J, Van Hoof A et al (2013) 90Yttrium-Ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol 31:1977–1983

    Article  PubMed  CAS  Google Scholar 

  38. Mossner E, Brunker P, Moser S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393–4402

    Article  PubMed  CAS  Google Scholar 

  39. Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279–4284

    Article  PubMed  CAS  Google Scholar 

  40. Nogai H, Dörken B, Lenz G (2011) Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 29:1803–1811

    Article  PubMed  CAS  Google Scholar 

  41. O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    Article  Google Scholar 

  42. Passweg R, Baldomero H, Bregni M et al (2013) Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant. 48: 1141–1147

  43. Pfeifer H, Wassmann B, Bethge W et al (2013) Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia. Leukemia 27:1254–1262

    Article  PubMed  CAS  Google Scholar 

  44. Press OW, Eary JF, Appelbaum FR et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219–1224

    Article  PubMed  CAS  Google Scholar 

  45. Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190–2196

    Article  PubMed  CAS  Google Scholar 

  46. Rajkumar SV (2013) Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88:226–235

    Article  PubMed  Google Scholar 

  47. Richardson PG, Siegel D, Baz R et al (2013) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121:1961–1967

    Article  PubMed  CAS  Google Scholar 

  48. Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259

    Article  PubMed  CAS  Google Scholar 

  49. Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42–51

    Article  PubMed  CAS  Google Scholar 

  50. Schaich M, Ehninger G (2012) Individualisierte Therapie der akuten myeloischen Leukämie. Onkologe 18:1084–1092

    Article  Google Scholar 

  51. Scholz CW, Pinto A, Linkesch W et al (2013) (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 31:308–313

    Article  PubMed  CAS  Google Scholar 

  52. Siegel DS, Martin T, Wang M et al (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817–2825

    Article  PubMed  CAS  Google Scholar 

  53. Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946–2955

    Article  PubMed  CAS  Google Scholar 

  54. Topp MS, Gökbuget N, Zugmaier G et al (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120:5185–5187

    Article  PubMed  CAS  Google Scholar 

  55. Wang M, Fayad L, Wagner-Bartak N et al (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13:716–723

    Article  PubMed  Google Scholar 

  56. Wang ML, Rule S, Martin P, et al. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 369(6):507–516

    Google Scholar 

  57. Weisberg E, Manley PW, Cowan-Jacob SW et al (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345–356

    Article  PubMed  CAS  Google Scholar 

  58. Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189

    Article  PubMed  CAS  Google Scholar 

  59. Zonder JA, Mohrbacher AF, Singhal S et al (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:552–559

    Article  PubMed  CAS  Google Scholar 

Download references

Einhaltung der ethischen Richtlinien

Interessenskonflikt. A. Hochhaus: Forschungsunterstützung und Honorare (Novartis, BMS, Ariad, Pfizer, MSD) P. La Rosée: Forschungsunterstützung und Honorare (Novartis, BMS, MSD). L.-O. Mügge: Forschungsunterstützung und Honorare (Celgene). H.G. Sayer: Forschungsunterstützung und Honorare (Novartis). S. Scholl: Honorare (Novartis, Jansen-Cilag).

Author information

Authors and Affiliations

  1. Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Erlanger Allee 101, 07740, Jena, Deutschland

    A. Hochhaus, P. La Rosée, L.-O. Mügge, H.G. Sayer & S. Scholl

Authors
  1. A. Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. La Rosée
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L.-O. Mügge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.G. Sayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Hochhaus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hochhaus, A., La Rosée, P., Mügge, LO. et al. Zielgerichtete Therapien bei hämatologischen Erkrankungen. Onkologe 19, 835–847 (2013). https://doi.org/10.1007/s00761-013-2497-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-013-2497-x

Schlüsselwörter

Keywords

Search

Navigation